cerecor inc hold chapter begin aevi asset transit come without risk
get downgrad hold analyst jason mccarthi ph full summari
 buy pt lower estim pt overreact coronaviru impact
inc buy pt mayb upsid still
rais pt analyst jason mccarthi ph full summari
inc buy pt solid quarter macro factor dilut pressur share
lower pt analyst jason mccarthi ph full summari
biolinerx ltd blrx buy pt reduc price higher expens capit need
inc buy pt new product build top-lin compress margin lower pt
hyrecar inc hyre buy pt preview fundament remain strong support sustain top-line growth
multipl year maintain buy pt analyst vander aard full summari
reed inc reed buy pt result disappoint new c-suit hire guid turnaround maintain buy
identiv inc buy pt guidanc unchang high qualiti manag well-posit market share
gain dust settl analyst nehal chokshi full summari
inc buy pt beat revenu retail momentum distribut expans
pluristem inc psti buy pt cell therapi pneumonia/inflamm
compon kill cell therapi may help analyst jason mccarthi ph full summari
navidea biopharmaceut inc navb buy pt arm data tc-til rheumatoid arthriti studi ahead
corpor event pleas contact maxim salesperson inform
venu concept inc vero cover vendetti product demonstr luncheon nyc kol dr neil sadick
ceo director domen serafino chad zare wed apr
maxim group infecti diseas confer nyc apli apm ard armp cdtx cfrx mtnb
scyx host mccarthi tue may
envis solar intern inc evsi cover sullivan ndr chicago ceo desmond wheatley wed
industri incorpor cover sullivan confer call ceo scott salmir cfo anthoni
graham corpor cover sullivan ndr boston cfo jeffrey glajch mon
graham corpor cover sullivan ndr nyc cfo jeffrey glajch tue
otter tail corpor cover sullivan ndr nyc ceo chuck macfarlan cfo kevin moug
alarm com cover chokshi confer call cfo steve valenzuela tue
pure storag inc cover chokshi ndr nyc cfo kevan chrysler thu apr
pure storag inc cover chokshi ndr boston cfo kevan chrysler fri apr
maxim group senior enterpris consum technolog analyst market boston chokshi mon apr
nutanix inc cover chokshi group lunch boston cfo duston tue apr
sustain top-line growth multipl year
ahead result increas revenu estim fit within
preliminari revenu rang
overwhelm major public compani expect materi busi
implic due coronaviru hyre busi appear fundament
sound driver demand car suppli util level remain robust
highlight recent partnership clutch technolog privat
attract growth catalyst facilit acceler dealership-list vehicl
suppli hyre platform
nr recent acquir divis hyre competitor call
flexdriv privat specul may serv potenti catalyst
hyre captur addit dealership vehicl suppli
project revenu increas compound-annual-growth-rate next three year along
adjust ebitda loss narrow turn posit
maintain buy rate price target
ahead result increas top-line estim strong demand
manag recent announc preliminari revenu expect hyre
schedul report result march post-clos remain confid
compani growth outlook near-term long-term rais
estim ahead releas januari hyre issu press
releas provid preliminari revenu result rang along
total rental day quarter day y/i result
slightli increas revenu estim y/i
prior estim consensu also slightli increas
adjust ebitda loss estim prior estim
compar consensu estim
hyre busi appear fundament sound driver demand car suppli
util level remain robust hyrecar issu press releas yesterday
morn march announc schedul earn releas also
includ addit busi insight regard accord comment provid
manag hyrecar continu benefit robust driver demand vehicl
util level new oem dealer partnership addit manag
indic hyre pace increas total rental day q/q reach
total rental day ahead impli project
rental day importantli manag also expect vehicl suppli
continu expand also maintain high level util retent
recent partnership clutch technolog present attract growth
catalyst facilit acceler dealership-list vehicl suppli hyre
platform februari hyre announc compani partner
clutch technolog brand own cox automot privat deliv
automot industri first comprehens share fleet on-demand mobil solut
dealership origin equip manufactur oem view partnership
signific increment posit direct support bullish growth thesi
compani center dealership opportun core sourc
vehicl suppli hyre platform share fleet on-demand mobil
solut design provid auto dealership oem auto provid
all-inclus solut leverag shift automot ownership access
grow consum demand mobil altern hyrecar dealer client
abl util clutch subscript softwar power varieti consumer-
centric transport solut singl vehicl subscript servic
pickup deliveri base check believ clutch telemat subscript
servic current serv dealership certain
mani vehicl current use clutch solut regardless view like
least portion dealer attach hyrecar solut well histor
new dealer partner join hyrecar ecosystem typic start slow list
vehicl initi ramp list vehicl time assum
clutch dealer partner also attach hyrecar solut would add increment
vehicl hyrecar platform assum averag vehicl per rooftop
view lyft recent acquisit certain asset own flexdriv
may creat addit opportun hyre increas vehicl suppli
flexdriv origin form joint ventur cox automot holman
enterpris privat one lyft long-stand drive partner
earn call manag announc compani
acquir flexdriv plu assum debt leas oblig close
februari howev base channel check understand
acquir portion flexdriv busi focus
advanc logist solut actual ownership electr vehicl howev
understand acquir consumer-bas flexdriv busi
close relat hyre offer anticip may creat opportun
hyrecar captur vehicl flexdriv dealer partner although
scenario benefit hyre would like assum flexdriv move toward
exit consumer-rel busi specul view
unclear viabl probabl scenario seem logic view
remain confid hyre long-term growth outlook expect multipl
catalyst stock expect onboard new dealership partner
number car alloc hyrecar per dealer caus investor start recogn
long-term revenu opportun specif project revenu increas
compound-annual-growth-rate next three year dealership contribut begin ramp
also expect gross margin steadili improv long-term compar
primarili due increas scale new
insur plan tier introduc april believ compani
track gener posit free cash flow expect long-term
oper margin exceed
maintain buy rate price target follow recent market-wid
sell-off hyre current trade revenu
estim respect price target base revenu estim
repres signific upsid current share price multipl
peer group averag consensu revenu estim believ
premium multipl justifi given hyre far attract long-term margin
structur project faster revenu growth next three year
price target also support dcf analysi base termin
period multipl wacc perpetu growth rate rate also
consid attract industri tailwind ride-shar monet asset
creat attract asset-light platform mostli recur revenu
descript hyrecar inc headquart lo angel california oper
web-bas car-shar marketplac unit state marketplac allow car
owner individu auto dealer rent idl car ride-shar servic
driver work compani strateg
partnership driveitaway passtim deliv dealer-focus vehicl track
inventori manag solut hyrecar inc found septemb
becam public compani june
click full note
lower estim pt overreact
coronaviru impact view reiter buy still
direct indirect effect coronaviru impact earn
fed fund rate cut
tech/biotech valuat affect warrant/
vc invest gain like ipo/m a/capit market activ
macroeconom growth slower thu dampen overal earn
lower ep estim
respect due factor mention base new estim
lower price target equat
new ep estim vs previous
highlight expect materi impact credit qualiti
remain best bank idea particularli recent stock correct
opinion creat opportun buy uniqu arguabl
best bank world less estim
lower ep estim lower ep estim
main reduct net interest incom
asset-sensit rate cut hurt net interest incom vice versa also
reduc client invest fee foreign exchang fee gain warrant
vc invest leerink revenu page updat earn model
expect materi impact credit qualiti magnitud impact
coronaviru depend part durat diseas time begin
reced take optimist view assum durat
materi impact credit qualiti measur net charge-
off note oil ga exposur
regard uniqu non-replic investor day decemb
manag highlight enjoy command market share
among earli stage technolog life scienc compani
power relationship vc backer offer
compani includ proprietari advic employe access
network peer industri expert develop global infrastructur
servic relev type compani grow therebi
enabl keep client lifespan acquisit leerink
partner add capit market servic advisori servic
gener signific synergi full-servic commerci invest
bank product offer help attract client captur greater share
client total bank need abl gener roe
even low-rat environ fed fund rate
reiter buy rate new price target share current trade
new ep estim estim new price target
equat price-to-earnings multipl new ep estim versu
previou price target in-line highest qualiti best-in-class smid-cap
bank remain top pick among smid-cap bank long term due
uniqu non-replic franchis growth implic franchis
share sinc coronaviru outbreak opinion
overreact accordingli reiter buy rate new price target
repres upsid
click full note
chapter begin aevi asset transit
come without risk get
downgrad hold
report wednesday morn net loss
end year cash note acquisit aevi genom
complet all-stock transact valu
payment reach futur mileston
compani rais februari equiti financ also
share aytu bioscienc aytu nr convert prefer stock
associ sale pediatr portfolio octob
said aevi acquisit view posit bring
sever potenti high-valu asset cash balanc get low
transit come without risk addit even reduc
expens like need rais capit may difficult
current environ therefor downgrad share hold buy
remov prior price target
model updat updat expens lower
compani transit away sale market cost
divestitur pediatr drugs/product portfolio given earli stage
develop factor modest platform valu aevi asset
formerli mab use risk
adjust rais path forward
strateg option determin along cash balanc low step
hold rate buy remov prior price target
aevi merger build rare diseas pipelin close merger transact
aevi transact valu stock less amount
aevi net asset lower maximum conting
valu right also issu aevi sharehold valu cash stock
choic aevi sharehold also receiv addit cash
stock approv within month transact
part strategi transit rare diseas focus compani also
includ divest neurolog pediatr asset sever asset ad
fmr mab human mab
develop auto-inflammatori diseas initi adult onset still diseas
aosd multipl myeloma mm condit patient show
increas level pro-inflammatori cytokin also correl
diseas sever aosd poor prognosi mm poc studi
aosd mm plan initi could produc data fairli
quickli aevi estim place data late
inhibitor phase readi develop lymphat malform lm
includ number orphan diseas combin preval
often high mortal approv therapi sinc diseas
caus pathway off-label use mtor inhibitor like
sirolimu inhibitor demonstr efficaci pr rate
howev lack approv toler issu black box warn stomat
limit use open label poc trial plan start
develop pediatr crohn diseas key inflammatori
mediat tnf superfamili express cell nk cell monocyt
granulocyt immatur dendrit cell elev tissu plasma
ibd patient also correl increas diseas activ phase
open-label studi adult crohn patient signal find studi on-going
initi data expect
click full note
turnaround maintain buy refocus compani
yesterday market close reed report result revenu
gm ep estim consensu
new ceo cfo hire compani refocus effort
optim suppli chain cut expens use target market
showcas brand
manag note effect busi
date monitor situat close
reed revis guidanc withdraw prior revenu estim
lower expect core brand growth
maintain gm estim
introduc estim revenu gm
loss per share
bottom line despit reed miss expect across board continu
optimist regard turnaround compani core brand reed virgil
appoint norman synder ceo februari manag
begin cut expens refocu market improv brand posit
addit believ compani grow innov includ new
reformul cbd infus hemp drink opinion oper
improv expand beverag portfolio drive growth
summari yesterday market close reed report revenu
y/i estim consensu
core brand gross sale flat y/i driven y/i volum growth virgil
off-set declin reed gross margin due approxim
inventori write-down year-end true-up inventori reserv exclud
item gross margin would y/i yet still significantli
lower estim consensu loss per share
slightli wider estim consensu
decemb compani cash equival
outstand debt
revis estim lower revenu estim
also slightli decreas gm estim
factor potenti impact also slightli narrow
gaap ep loss
guidanc revis reed withdrew annual revenu guidanc
note limit visibl manag also lower expect growth
core brand howev manag reiter
expect gross margin improv greater in-line
estim consensu
attract valuat reed trade revenu estim compar
peer averag price target base dcf analysi
discount rate perpetu growth rate impli ev/revenu
target estim believ premium valuat justifi due
expect eventu return peer revenu growth margin
click full note
mayb upsid still
rais pt
inovio report yesterday post-clos net loss
end period cash balanc sheet howev given
rise valuat recent week inovio also abl pull net proce
atm said cash current inovio
firmli driver seat multipl potenti inflect point
inovio play earli tell would view rise
valuat past week valid compani approach
use dna-bas immunotherapi rememb pivot stage compani
two trial cervic dysplasia one read
oncolog pipelin also robust driver data emerg
well view infecti diseas id even interest
valid platform long-term driver
combin reduc risk adjust
rais price target valuat perspect
rise would point advanc program
ask valu given size cervic dysplasia market
could plu opportun suggest addit upsid
share program alon id onc program could
model updat push though reduc risk adjust
combin minor chang pt rais
catalyst id initi studi vaccin healthi
volunt us april advanc mer field studi
middl east africa interim result dmab prevent
zika viru io partner io interim overal surviv data
regeneron nr glioblastoma
data gbm clinic trial sno complet studi
hnscc astrazeneca azn-nr potenti data readout esmo
intern io initi trial rrp interim efficaci data
vulvar/an dysplasia asccp reveal top-line data
cervic dysplasia
pivot studi target protein hpv viru
program includ studi reveal reveal patient
high-grad cervic dysplasia caus hpv subtyp reveal
studi random double-blind placebo-control patient studi
receiv intramuscular electropor cellectra day
placebo cellectra primari endpoint studi regress
lesion clearanc hpv viru cervix patient week
includ studi follow-up week reveal week
reveal remind reveal fulli enrol top-line data track
reveal site open global top-line data expect
click full note
solid quarter macro factor dilut
pressur share lower pt
report result yesterday post-clos revenu
net loss compani end period cash
exclud equiti financ complet estim
current cash hand provid fund
possibl longer depend launch trajectori
bivigam asceniv
launch bivigam asceniv progress accord expect
addit compani secur contract intermedi
fraction expect bring
valuat share trade low recent week
larg due macro factor impact market whole remain
posit fundament factor dilut associ
rais well macroeconom pressur lower price target
area focu
revenu growth- intermedi busi fifth
collect contract manufactur also first full year
commerci bivigam asceniv
commerci expansion- also focus expand manufactur
agreement announc potenti pipelin addit plasma
develop opportun
inventory- suppli build recal inventori
particularli import immunoglobulin igg suppli
demand imbal even though industri produc
igg suppli remain shortag consid month product cycl
market abl absorb produc
runway- compani approxim cash
provid runway flexibl properli launch asceniv bivigam
immunoglobulin could help respiratori virus place
downward pressur across market potenti disrupt suppli chain
facil florida still oper compani suppli chain
rel safe may also opportun use igg product
treatment particularli specialti hyperimmun product asceniv
rsv-special ivig report china emerg posit result
use plasma compon patient recov
hyperimmun igg asceniv deriv plasma patient high immun
titer respiratori pathogen asceniv current indic pidd primari
immun defici diseas product design use assay effect
identifi isol donor plasma high level antibodi respiratori
pathogen includ rsv multipl coronavirus could
use combin compani ip cover use igg
composit treat/prev type respiratori viral infect could
opportun treatment either asceniv licens
ip continu page
click full note
well-posit market share gain dust settl
result in-lin neg pre-announce result
high qualiti manag team posit market share gain
reiter buy rate price target
result in-lin neg pre-announce result yesterday market close
report revenu high-end neg pre-announce
guidanc y/i q/q gm contract y/
driven unfavor product mix within segment due lower video analyt
softwar sale premis thursbi deploy margin ident
ebitda y/i q/q estim
although full year ebitda y/i segment perspect
premis revenu declin y/i due uneven video analyt deploy
enterpris custom ident revenu y/i tough year
ago comparison y/i growth driven larg deploy thursbi solut
guidanc midpoint ebitda guidanc
midpoint ep rel
loss per share unexpect inventori build-up result
revenu reduct manag note impact suppli
chain disrupt caus limit new product launch
sale team expans manag also guid revenu season
stronger typic record sequenti declin larg
maintain full-year estim translat revenu estim
ebtida see januari note ebitda guidanc takedown bridg
gaap ep
high qualiti manag team posit market share gain
dust settl reiter buy rate price target big
pictur perspect continu believ ceo stephen humphrey cfo
sandra wallach bring level oper disciplin often found larger
compani highlight page initi report believ
manag team posit resourc activ creat
portfolio posit take share highli fragment market princip
advantag better reliabl speed structur lower price without
sacrif margin time manag improv sale product
salesforc believ well-posit withstand potenti recess
economi exit potenti recess would well-posit
continu share gain given inv result unchang guidanc
maintain ebitda estim dcf-driven price target
dcf framework emb terminal-period ebitda margin key
paramet includ long-term revenu compound-annual-growth-rate termin period gm
multipl termin year
click full note
beat revenu retail momentum distribut
today market open celsiu report better-than-expect
revenu estim consensu gm slightli
estim consensu ep rel in-line
increas dsd direct store deliveri distributor
partner prior quarter
march compani announc nationwid launch two sku
nr locat addit expand
relationship nr launch fifth sku store
increas revenu estim base quarter
beat expect continu growth new store locat
state disrupt suppli chain time
built roughli two month raw materi inventori prepar
bottom line report better-than-expect revenu continu
broaden distribut footprint deepen current account growth driven
higher sale volum higher veloc rate across channel trade
believ energi drink market remain robust gain consider
momentum expand new retail locat releas new flavor product
specif conveni store channel see continu growth retail
alloc shelf space accommod shift consum prefer remain
buyer opinion celsiu posit capit
macro trend deliv profit growth
result summari today market open report revenu
y/i estim consensu
gross margin y/i estim
consensu loss per share in-line estim
rel in-line consensu decemb
cash equival debt relat prior acquisit func food
increas estim due result expect increas
revenu estim
respect light manag expect record
impact adjust cadenc revenu estim
reflect shift sale maintain ep
estim expect higher oper expens off-set increas revenu
store expans march announc launch two
sku orang kiwi guava flavor function beverag nationwid
store begin largest us retail approxim
store throughout unit state addit expand relationship
includ expand offer newest flavor grapefruit melon green
launch locat carri five flavor
celsiu beverag
compel valuat share trade ev/revenu multipl
revenu estim compar peer averag price target base
dcf analysi discount rate termin growth rate
impli share trade revenu estim premium peer
believ justifi due differenti product signific above-p revenu
click full note
cell therapi pneumonia/
inflamm compon kill cell therapi may
pluristem announc collabor bih center regen
therapi bcrt berlin center advanc therapi becat
charit univers medicin berlin evalu plx cell treatment
respiratori inflammatori complic acut
stem cell emerg potenti treatment sever
symptom first mesoblast meso buy
pluristem though still earli stage stem cell safe demonstr
efficaci similar condit well relat pneumonia
could reduc mortal burden healthcar system
one import factor consid pluristem large-scal
manufactur cell therapi compani capabl
could critic point pluristem less depend extern suppli
chain could impact make better suit
deal outbreak
could stem cell new option second cell therapi
program know move treat ard follow
mesoblast meso buy see note link question cell therapi
help pandem view shot follow reason
anti-inflammatori properti stem cell like plx mesenchymal-lik
exert effect larg releas anti-inflammatory/immunomodulatori effect
main caus ard immun overreact lung
treat ard could reduc mortal healthcar burden
produc pneumonia sever case ard lead caus
relat death mani patient requir respiratori support place strain
healthcar system particularli itali second case
detail
efficaci respiratori diseas stem cell demonstr efficaci
pneumonia reduc time icu support care reduc
healthcar burden could invalu deal plx cell
also demonstr preclin efficaci respiratori condit
safeti stem cell tend favor safeti profil also
demonstr safeti pneumonia patient plx cell particular
establish safeti profil across hundr patient safeti profil could
advantag emerg use need
case support care develop therapeut side
larg focus antivir gilead hold remdesivir
among furthest develop two on-going data chines
studi expect april howev also need support care
sever patient accord statist china case mild
sever requir hospit critic requir intens care itali
sever outbreak outsid china see healthcar system
overwhelm outbreak report countri triag care treat
patient best chanc therapeut success countri also face
shortag ventil continu page
click full note
reduc price higher expens
capit need fundament remain sound
biolinerx report result morn net loss
end period cash balanc sheet expens risen
combat pancreat cancer studi genesi phase stem
expens came vs estim due rise cost
relat advanc clinic trial compani like go
need rais capit may difficult given current macro-
fundament remain sound upcom catalyst
see increas risk adjust
increas expens lower
price target
interim result aml consolid studi
top-lin result genesi registr studi stem cell mobil
initi result part part dose-
prior updat updat european societi medic oncolog
immuno-oncolog congress esmo io decemb present data
studi evalu motixafortid keytruda
chemotherapi second-lin metastat pancreat cancer oral present
entitl multi-cent phase trial assess safeti efficaci
inhibitor combin pembrolizumab chemotherapi patient
metastat pancreat adenocarcinoma pdac
cutoff date present data patient
evalu safeti evalu efficaci result demonstr
overal respons rate orr diseas control rate dcr
compar favor current chemotherapi soc treatment deliv
orr dcr respect furthermor patient
stabl diseas sd becam partial respond treatment continu partial
respond still treatment max treatment time day
patient experienc tumor shrinkag median durat clinic benefit
progress patient diseas control month
total enrol patient complet
await progress free surviv overal surviv os data
trial serv endpoint data expect note
compani also announc ema grant orphan drug design
motixafortid pancreat cancer
click full note
new product build top-lin compress margin
lower pt storag media well-posit
biolif report result yesterday post-clos revenu
y/i sequenti though consensu gross
margin came net incom though oper loss
expectedli slightli neg compani end period
cash balanc sheet share
manag issu guidanc revenu y/i
gross margin opex full-year profit expect
model updat base guidanc expect lower
estim particular lower revenu estim
rais total expens estim
compani integr lower margin product revenu expect grow
significantli narrow margin impact bottom line lower price
target
commerci updat biopreserv media came largest segment
total revenu sale y/i sequenti
key factor impact media revenu two custom cell therapi compani
distributor come forecast cell therapi custom miss
result decreas product demand led use exist media
inventori freezer revenu cb acquisit came despit deal
close mid-novemb autom thaw sale
product ship sinc april acquisit evo gener
revenu shipment made world-wide use
evo liquid nitrogen dewar saa cloud-bas cold chain manag platform
biolif ad nearli new custom confirm util
compani biopreserv media addit clinic trial addit new
therapi biolif custom expect file approv recal
everi approv product could repres recur revenu
bio buy iovanc nr orchard ortx nr
client biolif disclos addit regulatori file may occur
guidanc issu manag introduc guidanc includ revenu
y/i gross margin oper expens
full-year profit expect
impact disrupt suppli chain due pandem
remain threat biolif could potenti place pressur top-lin
key issu biolif locat basel washington mile
epicent us outbreak compani issu work
home direct addit compani key supplier base
china risk biolif suppli line howev compani approxim
month demand inventori impact fairli minim
also opportun seen cell therapi emerg potenti treatment
intent evalu remestemcel-l mesenchym stem cell treat acut
respiratori distress syndrom ard lead caus mortal
patient see note link pluristem psti buy
explor plx cell well continu page
click full note
arm data tc-til rheumatoid arthriti studi ahead
navidea report result yesterday post-clos net loss
cash balanc howev includ
addit fund sale ohio court judgment
concurr privat placement announc februari compani
estim runway complet trial final
arm interim data next mimic design act
read-through trial reach enrol expect data
trial expect initi trial
particularli import would enabl phenotyp predict respons
biolog initi
enrol progress typic rate rheumatoid arthriti ra
trial view posit signal show buy-in physician
rheumatolog nuclear medicin highlight need product
conclus navidea continu make substanti progress tc-til ra
arm data ahead second set initi navidea
also partnership discuss sever quarter
actual turn sever deal base manag comment
patienc may paid form higher valuat term sheet deal
could potenti final come month view
arm data ahead next major event navidea arm data
phase trial interim analysi arm healthi
subject patient stabl diseas abl confirm repeat
reproduc stabil tc-til imag establish quantit measur
healthi vs ra joint arm particularli import design mimic
act read-through well inform power arm pilot
arm upcom phase patient candid move anti-tnf
biolog therapi assess whether tc-til measur respons
anti-tnf interim readout plan enrol trial recent
achiev evalu chang baselin post therapi
start data collect complet come week posit interim
readout view arm data could use attract potenti
partner could provid sourc non-dilut fund pivot
second
enrol posit signal view enrol progress rapidli
rate subject per month per pi faster typic rate ra
trial view posit signal upcom
studi also potenti launch demonstr
buy-in rheumatologist nuclear medicin physician often
present challeng cross-disciplinari therapeut diagnost view
also repres way navidea run trial design base
kol input timepoint imag assess
click full note
maxim analyst coverag univers
sector coverag
care well
receiv full disclosur compani maxim group coverag mention report pleas send
